Article

Clinical study to validate ClarityDX Prostate as a reflex test to high PSA levels to refine prediction of clinically significant prostate cancer has begun in a prospective cohort of 2800 men.

Alberta-based Nanostics is hoping to recruit 200 Yukoners to the clinical validation study testing ClarityDX Prostate in a real-world setting.

The Yukon Ride for Dad, which raises money for prostate cancer awareness and research, is making a substantial investment in Nanostic’s research into diagnostic testing for prostate cancer.

News Medical Lifesciences – ClarityDX Prostate cancer diagnostic test validation study gets a boost in recruitment thanks to concurrent fundraising campaigns.

The Nanostics & APCaRI co-sponsored ClarityDX Prostate clinical validation study is expanding into the US by opening the Daytona Beach, Florida Century Clinical Research, Inc. recruitment site.

1 of 7 Canadian men is diagnosed with prostate cancer each year. We cannot emphasize enough on how important it is to get tested each year. Nanostics has come up with a non-invasive diagnostic test to bring clarity to healthcare decisions. Their core technology is in development to be able to diagnose prostate cancer from a simple blood test.

Nanostics’ core technology, ClarityDX, combines a sensitive extracellular vesicle detection platform with advanced machine learning to diagnose a disease from a simple blood test.

Ana Pena wrote for the Prostate Cancer News Today: The company says the diagnostic tool has the potential to spare many men unnecessary biopsies and treatments.

NEWS STAFF REPORT: Blood test predicts aggressive prostate cancer with greater accuracy and less patient discomfort.

CSO Desmond Pink discusses Nanostics’ productive partnership with DynaLIFE Medical labs’ Translational Research Program- a key relationship to bring ClarityDX to market.